Demonstrated Safety Profile in MEfRVO

The most common adverse reactions (5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1

VIBRANT, COPERNICUS, and GALILEO:
Most common adverse reactions (≥1%)1

1 / 3
2 / 3
3 / 3
3 / 3

Less common adverse reactions reported in <1% of the patients treated with EYLEA in the
CRVO studies were corneal edema, retinal tear, hypersensitivity, and endophthalmitis.1

Find out more about all
EYLEA indications

Reimbursement Support
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Product Support
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

News - Resources
Resources

Get the information you
and your patients need
about EYLEA.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

Reference
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021.